Shrihari Amruta Dalai
205501144
1. What are the risk factors for ovarian cancer?
The risk factors for ovarian cancer include:
[Link]-Most cases are diagnosed in women over 50 years old.
[Link] History- Mutations in BRCA1 and BRCA2 genes significantly heighten this risk.
[Link] History: Nulliparity, infertility, or late menopause are associated with a higher
risk of ovarian cancer.
4. Hormone Replacement Therapy (HRT): Prolonged use of estrogen-only hormone
replacement therapy after menopause may increase the risk.
[Link]: Women with a history of endometriosis are at a higher risk of developing
certain types of ovarian cancer.
2. Describe the staging of ovarian cancer.
Ovarian cancer staging is classified according to the FIGO (International Federation of
Gynecology and Obstetrics) staging system:
- **Stage I**: Cancer is confined to the ovaries.
- **IA**: Cancer is limited to one ovary, with no tumor on the ovarian surface; capsule
intact, and no malignant cells in ascites or peritoneal washings.
- **IB**: Cancer is present in both ovaries, with the same characteristics as Stage IA.
- **IC**: Cancer is in one or both ovaries with any of the following: capsule rupture, tumor
on the surface of one or both ovaries, malignant cells in ascites or peritoneal washings.
- **Stage II**: Cancer has spread to the pelvis.
- **IIA**: Extension and/or implants on the uterus and/or fallopian tubes.
- **IIB**: Extension to other pelvic tissues.
- **Stage III**: Cancer has spread beyond the pelvis to the peritoneum or retroperitoneal
lymph nodes.
- **IIIA**: Microscopic peritoneal metastasis beyond the pelvis.
- **IIIB**: Macroscopic peritoneal metastasis beyond the pelvis, up to 2 cm in size.
- **IIIC**: Macroscopic peritoneal metastasis beyond the pelvis greater than 2 cm, or
metastasis to retroperitoneal lymph nodes.
- **Stage IV**: Distant metastasis.
- **IVA**: Pleural effusion with positive cytology.
- **IVB**: Parenchymal metastases and metastasis to extra-abdominal organs (including
inguinal lymph nodes and lymph nodes outside the abdominal cavity).
Q3. How will you manage a case of adnexal mass 6 x 7 cm in a 40-year-old P3L3 lady?
Management of an adnexal mass in a 40-year-old P3L3 woman requires a comprehensive
approach involving clinical assessment, imaging, and possible surgical intervention:
1. **Clinical Evaluation**:
- Detailed history focusing on symptoms such as pelvic pain, bloating, urinary frequency,
and family history of ovarian or breast cancer.
- Physical examination, including pelvic examination to assess the size, mobility, and
consistency of the mass.
2. **Imaging**:
- **Transvaginal Ultrasound (TVS)**: The first-line imaging modality to evaluate the
characteristics of the adnexal mass. Features to assess include the size, solid or cystic
nature, septations, and presence of ascites.
- **Color Doppler**: To assess vascularity, which helps differentiate between benign and
malignant masses.
- **CT/MRI**: If TVS suggests malignancy or if further characterization is needed.
3. **Laboratory Tests**:
- **CA-125**: Tumor marker often elevated in epithelial ovarian cancer, but also in other
conditions like endometriosis, PID, and fibroids.
- Other markers like **HE4** and **ROMA score** can be considered if malignancy is
suspected.
4. **Risk Assessment**:
- Based on the RMI (Risk of Malignancy Index) or similar scoring systems, which consider
menopausal status, ultrasound findings, and CA-125 levels.
5. **Management Plan**:
- **Low Risk of Malignancy**:
- If the mass appears benign (e.g., simple cyst), conservative management with regular
follow-up and repeat imaging is an option.
- Consider surgical intervention if the mass persists or grows, causes symptoms, or if
there is uncertainty in the diagnosis.
- Laparoscopy is preferred over laparotomy for the removal of benign masses.
- **High Risk of Malignancy**:
- Surgical exploration is recommended, typically through laparotomy to ensure proper
staging if malignancy is confirmed.
- Intraoperative frozen section biopsy to guide the extent of surgery (e.g., oophorectomy
vs. full staging procedure).
- Referral to a gynecologic oncologist if malignancy is confirmed.
6. **Post-Operative Management**:
- Based on final histopathology. If benign, regular follow-up is sufficient.
- If malignant, appropriate staging and adjuvant therapy (chemotherapy) should be initiated
based on the stage and type of ovarian cancer.
7. **Counseling**:
- Discuss potential outcomes, including the possibility of malignancy, and the implications
of surgical intervention, such as fertility considerations and hormone replacement therapy if
oophorectomy is performed.
The approach must be individualized based on the patient's clinical findings, imaging results,
and risk assessment.